Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Graft-Versus-Host Disease
Interventions: Prochymal®; Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 70 Years
U.S. locations: 3
States / cities: Beech Grove, Indiana • Boston, Massachusetts • New York, New York

Conditions: Alzheimer Disease
Interventions: SPECT scan; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 50 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Stress Urinary Incontinence (SUI)
Interventions: Not listed
Lead sponsor: Atlantic Health System; Other
Eligibility: Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Atrial Fibrillation, Behavior
Interventions: Corrie Virtual Atrial Fibrillation Management Program; Combination Product
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Chronic Pain, Fatigue, Substance Use Disorders
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depressive Disorder, Major
Interventions: fMRI; Procedure
Lead sponsor: Duke University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Autism
Interventions: Eyelink Portable Duo, Integrated PCP Diagnosis and Eye-tracking Biomarker; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 14 Months to 48 Months
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Anderson, Indiana • Batesville, Indiana • Indianapolis, Indiana + 4 more

Conditions: Influenza
Interventions: Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Zika Virus Infection
Interventions: ZIKV Detect™ 2.0 IgM Capture ELISA; Other
Lead sponsor: InBios International, Inc.; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Small Cell Lung Cancer
Interventions: topotecan/cisplatin, etoposide/cisplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 66
States / cities: Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more

Conditions: Sickle Cell Disease
Interventions: sodium nitrite injection, usp; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 23 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure
Interventions: Collection of discarded heart tissue; Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 19 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pleural Infection Bacterial, Pleural Infections, Pleural Infections and Inflammations, Empyema, Pleural, Empyema, Complicated Pleural Effusion/ Empyema, Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion
Interventions: Fibrinolytic once daily, Fibrinolytic twice daily, DNA degradation once daily, DNA degradation twice daily; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Little Rock, Arkansas • Palo Alto, California • San Diego, California + 7 more

Conditions: Stroke
Interventions: Not listed
Lead sponsor: Rapid Medical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Grand Rapids, Michigan + 3 more

Conditions: Treatment Resistant Depression
Interventions: Diprivan; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Interventions: Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine; Biological · Combination Product
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 2,650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 31
States / cities: Anaheim, California • Lake Forest, California • Riverside, California + 26 more

Conditions: Diabetes Mellitus, Type 1
Interventions: SteadiSet Infusion Set; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obstructive Sleep Apnea Syndrome, Cleft Lip/Palate
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Uveal Melanoma
Interventions: Darovasertib, Crizotinib (Xalkori); Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 11
States / cities: Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 7 more

Conditions: Breast Cancer
Interventions: exemestane, Placebo; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 8
States / cities: Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Cystic Fibrosis
Interventions: Placebo, Tobi Podhaler; Drug · Device
Lead sponsor: Mylan Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Miami, Florida • Orlando, Florida • Pensacola, Florida + 4 more

Conditions: Schizophrenia
Interventions: BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo, BI 498306 25 mg QD, BI 409306 10 mg QD; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more

Conditions: Sepsis, Septicemia, Sepsis Syndrome, Shock, Septic, Community Acquired Pneumonia
Interventions: Not listed
Lead sponsor: National Center for Genome Resources; Other
Eligibility: 6 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina

Search by objective public record fields.

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

Single Incision Suburethral Sling at Time of Robotic Sacrocolpopexy

Mobile Health Technology-Enabled AFib Management

Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and Pharmacology

Neurobehavioral Mechanisms of Emotion Regulation in Depression Across the Adult Lifespan

Validation of Indiana's Early Evaluation Hub System

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA

Pilot Study to Assess the Proteome in Human Atrial Tissue

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

Identifying Targets of Maladaptive Metabolic Responses in Heart Failure

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

Cognition and Imaging With Tigertriever

Neural and Antidepressant Effects of Propofol (Phase 2)

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes

A Study to Examine the Relationship Between Sleep Apnea and Cleft Lip/Palate

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests